High levels of plasma high-density lipoproteins (HDL) are associated with a low incidence of cardiovascular disease[1]. HDL contains two major apolipoproteins (apo):apoAI and apoAII. It is generally accepted that apoA...High levels of plasma high-density lipoproteins (HDL) are associated with a low incidence of cardiovascular disease[1]. HDL contains two major apolipoproteins (apo):apoAI and apoAII. It is generally accepted that apoAI plays a central role in reverse cholesterol transport and protects against atherosclerosis[2,3]; however,apoAII functions have not been clearly characterized[4-6].展开更多
Background Cardiovascular disease (CVD) is mainly caused by atherosclerosis,for which dyslipidemia (i.e. high (V)LDL-cholesterol (C),high triglycerides and low HDLC is a major risk factor. To reduce the risk to develo...Background Cardiovascular disease (CVD) is mainly caused by atherosclerosis,for which dyslipidemia (i.e. high (V)LDL-cholesterol (C),high triglycerides and low HDLC is a major risk factor. To reduce the risk to develop CVD,patients with dyslipidemia are usually treated with lipid-lowering drugs including statins and fibrates.展开更多
文摘High levels of plasma high-density lipoproteins (HDL) are associated with a low incidence of cardiovascular disease[1]. HDL contains two major apolipoproteins (apo):apoAI and apoAII. It is generally accepted that apoAI plays a central role in reverse cholesterol transport and protects against atherosclerosis[2,3]; however,apoAII functions have not been clearly characterized[4-6].
文摘Background Cardiovascular disease (CVD) is mainly caused by atherosclerosis,for which dyslipidemia (i.e. high (V)LDL-cholesterol (C),high triglycerides and low HDLC is a major risk factor. To reduce the risk to develop CVD,patients with dyslipidemia are usually treated with lipid-lowering drugs including statins and fibrates.
